These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 8060993)

  • 21. Crystal structure of the topoisomerase II poison 9-amino-[N-(2-dimethylamino)ethyl]acridine-4-carboxamide bound to the DNA hexanucleotide d(CGTACG)2.
    Adams A; Guss JM; Collyer CA; Denny WA; Wakelin LP
    Biochemistry; 1999 Jul; 38(29):9221-33. PubMed ID: 10413496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.
    Ketron AC; Denny WA; Graves DE; Osheroff N
    Biochemistry; 2012 Feb; 51(8):1730-9. PubMed ID: 22304499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Topoisomerase II mediated DNA strand cleavage and antitumor activities against murine leukemia P388 of novel acridines].
    Kimura M
    Yakugaku Zasshi; 1994 May; 114(5):304-7. PubMed ID: 8014839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus].
    René B; Fossé P; Khélifa T; Jacquemin-Sablon A; Bailly C
    Bull Cancer; 1997 Oct; 84(10):941-8. PubMed ID: 9435795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.
    Pommier Y; Capranico G; Orr A; Kohn KW
    Nucleic Acids Res; 1991 Nov; 19(21):5973-80. PubMed ID: 1658748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the topoisomerase II-induced cleavage sites in the c-myc proto-oncogene. In vitro stimulation by the antitumoral intercalating drug mAMSA.
    Riou JF; Vilarem MJ; Larsen CJ; Riou G
    Biochem Pharmacol; 1986 Dec; 35(24):4409-13. PubMed ID: 3024649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expedient synthesis and anticancer evaluation of dual-action 9-anilinoacridine methyl triazene chimeras.
    Walunj D; Egarmina K; Tuchinsky H; Shpilberg O; Hershkovitz-Rokah O; Grynszpan F; Gellerman G
    Chem Biol Drug Des; 2021 Feb; 97(2):237-252. PubMed ID: 32772433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the DNA intercalators 4'-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage.
    Pommier Y; Minford JK; Schwartz RE; Zwelling LA; Kohn KW
    Biochemistry; 1985 Nov; 24(23):6410-6. PubMed ID: 3002440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility.
    Borgnetto ME; Zunino F; Tinelli S; Kas E; Capranico G
    Cancer Res; 1996 Apr; 56(8):1855-62. PubMed ID: 8620504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of cleavage complexes using reactive inhibitor derivatives.
    Kreuzer KN; Freudenreich CH; Pommier Y
    Methods Mol Biol; 2001; 95():89-99. PubMed ID: 11089223
    [No Abstract]   [Full Text] [Related]  

  • 32. Inhibition of RNA synthesis in vitro by acridines--relation between structure and activity.
    Piestrzeniewicz MK; Wilmańska D; Studzian K; Szemraj J; Czyz M; Denny WA; Gniazdowski M
    Z Naturforsch C J Biosci; 1998; 53(5-6):359-68. PubMed ID: 9679327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells.
    Bonjean K; De Pauw-Gillet MC; Defresne MP; Colson P; Houssier C; Dassonneville L; Bailly C; Greimers R; Wright C; Quetin-Leclercq J; Tits M; Angenot L
    Biochemistry; 1998 Apr; 37(15):5136-46. PubMed ID: 9548744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol.
    Yamashita Y; Kawada S; Nakano H
    Biochem Pharmacol; 1990 Feb; 39(4):737-44. PubMed ID: 2154993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mammalian topoisomerase II activity is modulated by the DNA minor groove binder distamycin in simian virus 40 DNA.
    Fesen M; Pommier Y
    J Biol Chem; 1989 Jul; 264(19):11354-9. PubMed ID: 2544590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The specificity of topoisomerase-mediated DNA cleavage defines acridine-induced frameshift specificity within a hotspot in bacteriophage T4.
    Masurekar M; Kreuzer KN; Ripley LS
    Genetics; 1991 Mar; 127(3):453-62. PubMed ID: 1849858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
    Finlay GJ; Atwell GJ; Baguley BC
    Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stimulation of topoisomerase II mediated DNA cleavage at specific sequence elements by the 2-nitroimidazole Ro 15-0216.
    Sørensen BS; Jensen PS; Andersen AH; Christiansen K; Alsner J; Thomsen B; Westergaard O
    Biochemistry; 1990 Oct; 29(41):9507-15. PubMed ID: 2176847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracellular molecular interactions of antitumor drug amsacrine (m-AMSA) as revealed by surface-enhanced Raman spectroscopy.
    Chourpa I; Morjani H; Riou JF; Manfait M
    FEBS Lett; 1996 Nov; 397(1):61-4. PubMed ID: 8941714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA sequence preferences at sites cleaved by human DNA topoisomerase II in response to novel quinolone derivatives.
    Huff AC; Robinson RG; Evans AC; Selander KN; Wentland MP; Rake JB; Coughlin SA
    Anticancer Drug Des; 1995 Apr; 10(3):251-76. PubMed ID: 7748459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.